| Immunotherapy as a neoadjuvant therapy for a patient with hepatocellular carcinoma in the pretransplant setting: a case report M Abdelrahim, A Esmail, G Umoru, K Westhart, A Abudayyeh, A Saharia, ... Current Oncology 29 (6), 4267-4273, 2022 | 30 | 2022 |
| Hepatitis B virus reactivation in cancer patients treated with immune checkpoint inhibitors EA Burns, IN Muhsen, K Anand, J Xu, G Umoru, AN Arain, M Abdelrahim Journal of Immunotherapy 44 (3), 132-139, 2021 | 25 | 2021 |
| Gemcitabine and cisplatin as neo-adjuvant for cholangiocarcinoma patients prior to liver transplantation: case-series M Abdelrahim, H Al-Rawi, A Esmail, J Xu, G Umoru, F Ibnshamsah, ... Current Oncology 29 (5), 3585-3594, 2022 | 14 | 2022 |
| Gemcitabine Plus Cisplatin Versus Non-Gemcitabine and Cisplatin Regimens as Neo-adjuvant Treatment for Cholangiocarcinoma Patients Prior to Liver Transplantation: An … M Abdelrahim, A Esmail, J Xu, G Umoru, H Al-Rawi, A Saharia, ... Frontiers in Oncology 12 (10.3389/fonc.2022.908687), 908687, 2022 | 12 | 2022 |
| Pancreatic tumorigenesis: Precursors, genetic risk factors and screening M Badheeb, A Abdelrahim, A Esmail, G Umoru, K Abboud, E Al-Najjar, ... Current Oncology 29 (11), 8693-8719, 2022 | 8 | 2022 |
| Opportunistic infections in patients receiving daratumumab regimens for multiple myeloma (MM) EA Burns, JE Ensor, K Anand, C Gentille, C Guerrero, RB Kieser, ... Blood 138, 4740, 2021 | 7 | 2021 |
| Immune checkpoint inhibitors for solid tumors in the adjuvant setting: current progress, future directions, and role in transplant oncology K Abboud, G Umoru, A Esmail, A Abudayyeh, N Murakami, HO Al-Shamsi, ... Cancers 15 (5), 1433, 2023 | 6 | 2023 |
| A case report of neurotoxicity after prolonged doses of acyclovir in a patient with renal dysfunction GO Umoru, PJ Shah, F Tariq Journal of Pharmacy Practice 33 (2), 217-221, 2020 | 5 | 2020 |
| Paraneoplastic syndromes: A focus on pathophysiology and supportive care C Chung, E Allen, G Umoru American Journal of Health-System Pharmacy 79 (22), 1988-2000, 2022 | 4 | 2022 |
| Pulmonary arterial hypertension in breast cancer patients on HER2-targeted therapy: a review of FDA Adverse Events Reporting System data G Umoru, M Taitano, S Beshay, P Niravath, S Sahay ERJ Open Research 6 (2), 2020 | 4 | 2020 |
| Sequencing and combination of current small‐molecule inhibitors for chronic lymphocytic leukemia: Where is the evidence? C Chung, G Umoru, K Abboud, E Hobaugh European Journal of Haematology 111 (1), 15-28, 2023 | 3 | 2023 |
| Impact of Infections in Patients Receiving Pembrolizumab-Based Therapies for Non-Small Cell Lung Cancer EA Burns, K Gee, RB Kieser, J Xu, Y Zhang, A Crenshaw, IN Muhsen, ... Cancers 15 (1), 81, 2022 | 3 | 2022 |
| P-168 Combination of gemcitabine plus cisplatin compared to non-gemcitabine and cisplatin regimens as neo-adjuvant treatment in liver transplant recipients with cholangiocarcinoma M Abdelrahim, A Esmail, J Xu, G Umoru, H Al-Rawi, A Saharia Annals of Oncology 33, S309-S310, 2022 | 3 | 2022 |
| P-169 Feasibility of gemcitabine plus cisplatin as neo-adjuvant in cholangiocarcinoma patients prior to liver transplantation A Esmail, J Xu, G Umoru, H Al-Rawi, A Saharia, M Abdelrahim Annals of Oncology 33, S310, 2022 | 3 | 2022 |
| Adverse Effects and Non-Relapse Mortality of BCMA-Directed Immunotherapies: An FDA Adverse Event Reporting System (FAERS) Database Study Z Gong, G Umoru, J Monge, N Shah, GR Mohyuddin, S Radhakrishnan, ... Blood 142, 358, 2023 | 2 | 2023 |
| Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study Z Gong, G Umoru, J Monge, N Shah, GR Mohyuddin, SV Radhakrishnan, ... Blood cancer journal 14 (1), 36, 2024 | 1 | 2024 |
| Extended duration letermovir in allogeneic hematopoietic stem cell transplant B Hinman, J Cox, G Umoru, R Kamble, W Musick Transplant Immunology 81, 101936, 2023 | 1 | 2023 |
| Outcomes of patients with advanced urothelial cancer who develop infection while on treatment with pembrolizumab. RB Kieser, J Xu, E Burns, I Muhsen, SM Shah, G Umoru, C Mylavarapu, ... Journal of Clinical Oncology 40 (16_suppl), 4573-4573, 2022 | 1 | 2022 |
| Infections and their impact on patients on pembrolizumab-based therapies for head and neck cancer. Y Zhang, J Xu, I Muhsen, E Burns, SM Shah, G Umoru, C Mylavarapu, ... Journal of Clinical Oncology 40 (16_suppl), 6035-6035, 2022 | 1 | 2022 |
| Hepatitis B reactivation with pembrolizumab, atezolizumab, and nivolumab: A pharmacovigilance study and literature review. I Muhsen, E Burns, G Umoru, A Arain, J Xu, M Abdelrahim Journal of Clinical Oncology 38 (15_suppl), e15127-e15127, 2020 | 1 | 2020 |
Maen AbdelrahimHouston Methodist Cancer Center在 houstonmethodist.org 的电子邮件经过验证
